EUCTR2018-001438-16-PL招募中1 期
The GLORIA Study: A Phase 3, Randomized, Open-Label Study of the Anti-Globo H Vaccine Adagloxad Simolenin (OBI-822)/OBI-821 in the Adjuvant Treatment of Patients with High-Risk, Early-Stage Globo H-Positive Triple Negative Breast Cancer - GLORIA
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 668
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •1. Male or female patient =18 years.
- •2. Documented radiographic and histopathologic confirmed primary localized invasive breast cancer.
- •3. Histologically documented TNBC (estrogen receptor-negative [ER-] / progesterone receptor-negative [PR-] / human epidermal growth factor 2-negatove [HER2-]) defined as ER-negative and PR-negative (=5% positive cells stain by IHC for both ER and PR), and negative HER2/neu- status, confirmed on tumor sample.
- •- HER2/neu-negative will be defined as one of the following criteria:
- •- IHC 0 or 1+
- •- Single-probe average HER2 gene copy number of <6 signals/nucleus
- •- Dual-probe fluorescent in-situ hybridization (FISH) HER2/neu chromosome 17
- •(CEP17) non-amplified ratio of <2
- •4. Globo H IHC H-score =15 from the residual primary site/or lymph node (if primary site is not available) tumor obtained at the time of definitive surgery or initial diagnosis (only if surgical tumor sample is not available). Globo H expression will be determined during pre-screening by central lab. Instructions for submission of slides/tumor tissue blocks are provided in the protocol and study Lab Manual.
- •5. No evidence of metastatic disease in chest, abdomen, and pelvis by CT or other adequate imaging during the Screening Phase. Imaging within 3 months prior to randomization is acceptable as baseline scan. Bone scans and imaging of the brain at screening is optional, and should be symptom directed.
- •6. High-risk patients with no evidence of disease after completing standard treatment and meeting ONE of the following criteria:
- •- Neoadjuvant chemotherapy followed by definitive surgery: Residual invasive
- •disease following neoadjuvant chemotherapy defined as: A contiguous focus of
- •residual invasive cancer in the surgical breast specimen measuring =1 cm in
- •diameter and/or with residual invasive cancer in at least one axillary node
- •(micrometastases or macrometastases), as determined by local pathology review.
- •- Definitive surgery followed by adjuvant chemotherapy: Pathological Prognostic Stage IIB, Stage IIIA, IIIB, or Stage IIIC disease according to the 8th edition of the American Joint Committee on Cancer (AJCC) Cancer Staging Manual.
- •7. Must have completed at least 4 cycles of a standard taxane and anthracycline-based multi-agent chemotherapy regimen (or a taxane-only regimen if the patient is ineligible for anthracycline treatment) either in the neoadjuvant or adjuvant setting (e.g., National Comprehensive Cancer Network recommended regimens).
- •8. Randomization must occur (a) within 16 weeks after definitive surgery and radiation therapy (if radiation therapy administered) in patients who received neoadjuvant multiagent chemotherapy or, (b) for patients receiving adjuvant multiagent chemotherapy, within 16 weeks after the completion of the adjuvant multiagent chemotherapy and radiation therapy (if radiation therapy administered). Note: patients may be randomized and initiate study treatment concurrent with adjuvant SOC therapy (capecitabine).
- •9. All treatment-related toxicities resolved to Grade <1 on National Cancer
- •Institute-Common Terminology Criteria for Adverse Events (version 5.0) criteria (except hair loss and =Grade 2 neuropathy, which are acceptable).
- •10. Eastern Cooperative Oncology Group (ECOG) performance status =1.
- •11. Females must be either of non-childbearing potential, i.e., surgically sterilized (have documented sterilization, bilateral oophorectomy /salpingectomy at least 3 months before the start of the trial and/or hystere
排除标准
- •1. Local recurrence of or previous history of any ipsilateral or contralateral invasive breast cancer within 10 years prior to randomization [for synchronous tumors see Exclusion Criteria #3].
- •2. Definitive clinical or radiologic evidence of metastatic disease.
- •3. Synchronous bilateral breast cancer, unless both tumors are confirmed as TNBC.
- •4. Have received any post-operative immunotherapy with antigen, antibody, immune checkpoint inhibitors (Programmed cell death-1 [PD-1]/ Programmed cell deathligand- 1 [PD-L-1] inhibitors, anti-cytotoxic T-lymphocyte-associated protein 4 [CTLA-4] therapy), or other anti-cancer vaccines (neoadjuvant receipt of immune checkpoint inhibitors will not be exclusionary if the patient meets all other eligibility criteria).
- •5. Concomitant treatment with anticancer therapy other than adjuvant SOC therapy (capecitabine), or other investigational therapy, if expected during the study.
- •6. A history of other malignancies (except appropriately treated melanoma in situ, non-melanoma skin carcinoma, carcinoma in situ of the uterine cervix, follicular or papillary thyroid cancer or other non-breast malignancies with a similar outcome to those mentioned above) within 5 years prior to randomization.
- •7. Have any active autoimmune disease or disorder that requires systemic
- •immunosuppressive/immunomodulatory therapy. NOTE: Autoimmune diseases that are confined to the skin (e.g., psoriasis) that can be treated with topical steroids alone are allowed during the study.
- •8. Oral/parenteral corticosteroid treatment (>5 mg/day of prednisone /equivalent), within 2 weeks prior to randomization or anytime during the study. NOTE: inhaled steroids for treatment of asthma; and topical steroids are allowed.
- •9. Any known uncontrolled concurrent illness that would limit compliance with study requirements, including but not limited to ongoing or active infections, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, psychiatric disorders, or substance abuse.
- •10. Any known hypersensitivity to active/inactive ingredients in the study drug
- •formulation or known severe allergy or anaphylaxis to fusion proteins.
- •11. Prior receipt of a glycoconjugate vaccine for cancer immunotherapy.
- •12. Known history or positive for human immunodeficiency virus (HIV) positive, unless on effective anti-retroviral therapy with undetectable viral load within 6 months of therapy (note: HIV testing is not required for study entry).
- •13. Known active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection prior to randomization. Patients who have completed curative therapy for HCV are eligible. For patients with evidence of chronic HBV infection, the HBV viral load must be undetectable on suppressive therapy. (note: HBV/HCV testing is not required for study entry).
- •14. Any condition, including significant diseases and/or laboratory abnormalities that would place the patient at unacceptable risk for study participation.
- •15. Currently pregnant or breastfeeding women.
- •16. Currently participating in or has participated in a breast cancer therapeutic clinical trial within 4 weeks (28 days) prior to randomization.
研究者
相似试验
招募中
不适用
The GLORIA Study: A Phase 3, Randomized, Open-Label Study of theAnti-Globo H Vaccine Adagloxad Simolenin (OBI822)/OBI-821 in the AdjuvantTreatment of Patients with HighRisk, Early-Stage Globo H-Positive TripleNegative Breast CancerKCT0005816ovotech Asia Korea668
招募中
1 期
Phase 3 Study of Adagloxad Simolenin (OBI-822)/OBI-821 Treatment for Breast Cancer PatientsTriple Negative Breast CancerMedDRA version: 20.0Level: PTClassification code: 10075566Term: Triple negative breast cancer Class: 100000004864CTIS2023-508755-39-00Obi Pharma Inc.668
招募中
3 期
The GLORIA Study: A Phase 3, Randomized, Open-Label Study of the Anti-Globo H Vaccine Adagloxad Simolenin (OBI 822)/OBI 821 in the Adjuvant Treatment of Patients with High Risk, Early-Stage Globo H-Positive Triple Negative Breast CancerC50 Cancer de mamaPER-026-21OBI PHARMA, INC13
进行中（未招募）
1 期
Study of efficacy and safety of the compound NGR-hTNF in patient with advanced malignant pleural mesotheliomapplicableEUCTR2009-016879-29-GBMOLMED400
进行中（未招募）
1 期
GR015: Randomized double-blind phase III study of NGR-hTNF plus best investigator s choice (BIC) versus placebo plus BIC in previously treated patients with advanced malignant pleural mesothelioma (MPM) - NGR015Patients with advanced malignant pleural mesothelioma (MPM)previously treated with pemetrexedMedDRA version: 12.1Level: LLTClassification code 10035605Term: Pleural mesothelioma malignant advancedEUCTR2009-016879-29-ITMOLMED390